Letter: Rifaximin Versus Low <scp>FODMAP</scp> Diet in <scp>IBS</scp> : What the Primary Endpoint Does Not Tell Us

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2026-01-29
DOI
https://doi.org/10.1111/apt.70533
Citations
1
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
33.53

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Letter: Rifaximin Versus Low FODMAP Diet in IBS : What the Primary Endpoint Does Not Tell Us

Luisa Bertin, Edoardo Vincenzo Savarino
1 citations
Alimentary Pharmacology & Therapeutics
Gastrointestinal motility and disorders
33.53
article

Letter: Rifaximin Versus Low FODMAP Diet in IBS : What the Primary Endpoint Does Not Tell Us

Luisa Bertin, Edoardo Vincenzo Savarino
article en
1 citations

Abstract

No abstract available for this paper.
Alimentary Pharmacology & TherapeuticsVol. 63(6)
University of Padua (IT)
Pfizer
Good health and well-being
Openalex Percentile: Top 1%
Gastrointestinal motility and disorders
33.53
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.